The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study.
Adolescent
Adult
Aged
Body Mass Index
Cohort Studies
Diabetes Mellitus, Type 2
/ complications
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Female
Humans
Hypoglycemic Agents
/ classification
Incretins
/ therapeutic use
Male
Metformin
/ therapeutic use
Middle Aged
Obesity
/ complications
Obesity Management
Retrospective Studies
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Sulfonylurea Compounds
/ adverse effects
Thiazolidinediones
/ adverse effects
Weight Gain
Weight Loss
Weight Reduction Programs
Young Adult
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
accepted:
29
07
2019
pubmed:
1
8
2019
medline:
26
2
2021
entrez:
1
8
2019
Statut:
ppublish
Résumé
To compare weight change in a lifestyle-based weight management programme between participants taking weight-gaining, weight-neutral/loss and mixed diabetes medications. Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non-surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions. All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m Participants on weight-neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight-gaining medications. Diabetes medications should be reviewed ahead of planned weight-loss interventions to help ensure maximal effectiveness of the intervention.
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Hypoglycemic Agents
0
Incretins
0
Sodium-Glucose Transporter 2 Inhibitors
0
Sulfonylurea Compounds
0
Thiazolidinediones
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-255Informations de copyright
© 2019 Diabetes UK.
Références
Scottish Diabetes Survey 2016. Available at http://www.diabetesinscotland.org.uk Last accessed 8 September 2017.
Sattar N. Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Pract Research Cli Endocrinol Metab 2013; 2: 501-507.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
National Institute for Health and Clinical Excellence. Type 2 Diabetes in Adults: Management. NG 28 Available at www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf 1837338615493 Last accessed 10 December 2016.
American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes. Diabetes Care 2018; 41: S65-S72.
Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract 2007; 61: 19-28.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi_benedetti M, Moules IK et al.; PROative Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle H et al.; EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-1823.
Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-566.
Food Standards Agency 2007. Eatwell Plate. Available at http://www.food.gov.uk/multimedia/pdfs/publication/eatwellplate0907.pdf Last accessed 13 June 2016.
British National Formulary. Antidiabetic Drugs. Available at http://www.evidence.nhs.uk/formulary/bnf Last accessed 2 March 2016.
Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008; 120: 5-17.
Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L et al.; NN8022-1807 Study Group. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
Dixon KJ, Shcherba S, Kipping RR. Weight loss from three commercial providers of NHS primary care slimming on referral in North Somerset: service evaluation. J Public Health (Oxf) 2012; 34: 555-561.
Morrison DS, Boyle S, Morrison C, Allardice G, Greenlaw N, Forde L. Evaluation of the first phase of a specialist weight management programme in the UK National Health Service: prospective cohort study. Public Health Nutr 2011; 15: 28-38.
Poobalan AS, Aucott LS, Smith WC, Avenell A, Jung R, Broom J. Long-term weight loss effects on all-cause mortality in overweight/obese populations. Obes Rev 2007; 8: 503-513.
Diabetes UK 2017. Top 10 research priorities for Type 2 diabetes uncovered. Available at http://www.diabetes.org.uk/About_us/News/Top-10-Type2-research-priorities Last accessed 31 May 2018.
Hartmann B, Bramlage P, Schneider S, Tschope D, Gitt AK. Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort. Acta Diabetol 2015; 52: 1093-1101.
Ewenighi CO, Dimkpa U, Adejumo BI, Onyeanusi JC, Nnatuanya IN, Simon U et al. The effect of age, gender, level of adiposity and diabetes duration on glycated hemoglobin reduction after anti-diabetic therapy in type-2 diabetic patients. J Diabetes Mellitus 2012; 2: 245-250.
Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
Kostev K, Rex J, Rockel T, Heilmaier C. Effects of selected antidiabetics on weight loss-a retrospective database analysis. Prim Care Diabetes 2015; 9: 74-77.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551.
Botha S, Forde L, MacNaughton S, Shearer R, Lindsay R, Sattar N et al. Effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non-interventional outcomes at 3 years. Diabetes Obes Metab 2018; 20: 879-888.
Moroshko I, Brennan L, O'Brien P. Predictors of dropout in weight loss interventions: a systematic review of the literature. Obes Rev 2011; 12: 912-934.